Although the sarcoma breakdown list was not provided in that study, from the analytical result that MDM2, TP53, and RB1 were discriminative genes, one can expect that a significant portion of the dataset comprised liposarcoma and complex karyotype sarcomas such as leiomyosarcoma and osteosarcoma, which are currently not subjects of targeted therapy. This evidence concerns the gene MDM2 and liposarcoma.